Author: Ken Dropiewski

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) […]

LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development

SHENZHEN, China, April 2, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its…

Innovating “Treadmill Exercise Test AI-Assisted Interpretation System,” CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

TAICHUNG, Taiwan, April 2, 2024 /PRNewswire/ — The treadmill exercise test (TET) is an important tool for diagnosing coronary artery disease (CAD), but limited by time spent for the manual interpretation of a dozen charts and the challenges in identifying minor deviations. Traditionally,…

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Haemonetics Corporation Completes Acquisition of Attune Medical

BOSTON, April 1, 2024 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device. EnsoETM is the only FDA-cleared temperature regulation device indicated for esophageal protection […]

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NAARDEN, the Netherlands and MIAMI, April 01, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Juliette Audet as Chief Business Officer (“CBO”), and her simultaneous resignation from the Company’s Board of Directors, both effective April 1, 2024.